Patients who have breast cancer, especially triple-negative breast cancer (TNBC) lacking estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) benefit from pembrolizumab monotherapy and atezolizumab monotherapy significantly (5, 6). This evidence concerns the gene ESR1 and triple-negative breast carcinoma.